Article List
List all articles in the database by earliest discovery_date
GET /articles/?format=api&page=2437
{ "count": 24882, "next": "http://api.gregory-ms.com/articles/?format=api&page=2438", "previous": "http://api.gregory-ms.com/articles/?format=api&page=2436", "results": [ { "article_id": 527, "title": "Population-based head-to-head comparison of the clinical characteristics and epidemiology of AQP4 antibody-positive NMOSD between two European countries", "summary": "<div><p>Mult Scler Relat Disord. 2021 Mar 3;51:102879. doi: 10.1016/j.msard.2021.102879. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:p1=\"http://pubmed.gov/pub-one\" xmlns:xlink=\"http://www.w3.org/1999/xlink\">BACKGROUND: Population-based clinical studies in neuromyelitis optica spectrum disorder (NMOSD) and epidemiological and clinical comparisons of White ethnicities are missing. In a large population-based international cohort, we extensively characterized aquaporin-4 antibody seropositive (AQP4-Ab+) NMOSD, and also compared the clinical, radiological and epidemiological features between two European populations residing in different areas.</p><p xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:p1=\"http://pubmed.gov/pub-one\" xmlns:xlink=\"http://www.w3.org/1999/xlink\">METHODS: Between self-reported Danish and Hungarian ethnicities, we compared the population-based clinical features, disability outcomes, and death of 134 AQP4-Ab+ NMOSD cases fulfilling the 2015 International Panel for NMO Diagnosis (IPND) criteria. For precise comparison of epidemiology, we conducted a population-based head-to-head comparative study of the age-standardized prevalence (January 1, 2014) and incidence (2007-2013) of AQP4-Ab+ NMO/NMOSD among adults (≥16 years) in Denmark (4.6 million) and Hungary (6.4 million) by applying 2015 IPND (NMOSD) criteria and 2006 Wingerchuk (NMO).</p><p xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:p1=\"http://pubmed.gov/pub-one\" xmlns:xlink=\"http://www.w3.org/1999/xlink\">RESULTS: Danes were more likely to present with transverse myelitis and were more affected by spinal cord damage on long-term disability. Hungarians presented most often with optic neuritis, although visual outcome was similar in the groups. No differences were observed in sex, disease course, relapse rate, autoimmune comorbidity, mortality, brain MRI, and treatment strategies. The age-standardized prevalence estimates of AQP4-Ab+ NMOSD (2015 IPND criteria) in Denmark vs. Hungary were 0.66 vs. 1.43 (/100,000) while incidence rates were 0.04 vs. 0.11 (/100,000 person-years); similar differences were found based on the 2006 NMO criteria.</p><p xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:p1=\"http://pubmed.gov/pub-one\" xmlns:xlink=\"http://www.w3.org/1999/xlink\">CONCLUSIONS: This head-to-head comparative study indicates different disease characteristics and epidemiology among White populations in Europe, and substantiates the need for population-based genetic and environmental studies in NMOSD.</p><p>PMID:<a href=\"https://pubmed.ncbi.nlm.nih.gov/33714126/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210314083920&v=2.14.3\">33714126</a> | DOI:<a href=\"https://doi.org/10.1016/j.msard.2021.102879\">10.1016/j.msard.2021.102879</a></p></div>", "link": "https://pubmed.ncbi.nlm.nih.gov/33714126/#x3D;Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc&#x", "published_date": "2021-01-06T00:00:00Z", "sources": [ "PubMed" ], "teams": [ { "id": 1, "name": "Team Gregory" } ], "subjects": [ { "subject_name": "Multiple Sclerosis", "description": null } ], "publisher": "Elsevier BV", "container_title": "Multiple Sclerosis and Related Disorders", "authors": [ { "author_id": 244191, "given_name": "Papp", "family_name": "Viktoria", "ORCID": null, "country": null }, { "author_id": 244192, "given_name": "Kim D.P.", "family_name": "Trones", "ORCID": null, "country": null }, { "author_id": 167429, "given_name": "Melinda", "family_name": "Magyari", "ORCID": "http://orcid.org/0000-0002-0972-5222", "country": null }, { "author_id": 182576, "given_name": "Nils", "family_name": "Koch-Henriksen", "ORCID": "http://orcid.org/0000-0001-7985-7573", "country": null }, { "author_id": 195573, "given_name": "Anna", "family_name": "Iljicsov", "ORCID": "http://orcid.org/0000-0002-5442-0794", "country": null }, { "author_id": 193154, "given_name": "Cecília", "family_name": "Rajda", "ORCID": "http://orcid.org/0000-0002-0252-4778", "country": null }, { "author_id": 236855, "given_name": "Helle H.", "family_name": "Nielsen", "ORCID": null, "country": null }, { "author_id": 244193, "given_name": "Gabor", "family_name": "Lovas", "ORCID": null, "country": null }, { "author_id": 193783, "given_name": "Csilla", "family_name": "Rozsa", "ORCID": "http://orcid.org/0000-0001-9415-6177", "country": null }, { "author_id": 244194, "given_name": "Bjørn H.", "family_name": "Kristiansen", "ORCID": null, "country": null }, { "author_id": 194950, "given_name": "Egon", "family_name": "Stenager", "ORCID": "http://orcid.org/0000-0002-4877-5193", "country": null }, { "author_id": 160457, "given_name": "Jette Lautrup", "family_name": "Frederiksen", "ORCID": "http://orcid.org/0000-0003-1661-7438", "country": null }, { "author_id": 244195, "given_name": "Samuel", "family_name": "Komoly", "ORCID": null, "country": null }, { "author_id": 160395, "given_name": "Finn", "family_name": "Sellebjerg", "ORCID": "http://orcid.org/0000-0002-1333-9623", "country": null }, { "author_id": 227435, "given_name": "Thor", "family_name": "Petersen", "ORCID": "http://orcid.org/0000-0001-5633-2600", "country": null }, { "author_id": 163649, "given_name": "Zsolt", "family_name": "Illes", "ORCID": "http://orcid.org/0000-0001-9655-0450", "country": null } ], "relevant": null, "ml_prediction_gnb": false, "ml_prediction_lr": false, "ml_prediction_lsvc": false, "discovery_date": "2021-03-14T12:39:21Z", "noun_phrases": [ "head", "the clinical characteristics", "epidemiology", "AQP4 antibody-positive NMOSD", "two European countries" ], "doi": "10.1016/j.msard.2021.102879", "access": "open", "takeaways": " Danes were more likely to present with transverse myelitis and were more affected by spinal cord damage on long-term disability . Hungarians presented most often with optic neuritis, although visual outcome was similar in the groups .", "categories": [] }, { "article_id": 526, "title": "MPRAGE to MP2RAGE UNI translation via generative adversarial network improves the automatic tissue and lesion segmentation in multiple sclerosis patients", "summary": "<div><p>Comput Biol Med. 2021 Feb 26;132:104297. doi: 10.1016/j.compbiomed.2021.104297. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:p1=\"http://pubmed.gov/pub-one\" xmlns:xlink=\"http://www.w3.org/1999/xlink\">BACKGROUND AND OBJECTIVE: Compared to the conventional magnetization-prepared rapid gradient-echo imaging (MPRAGE) MRI sequence, the specialized magnetization prepared 2 rapid acquisition gradient echoes (MP2RAGE) shows a higher brain tissue and lesion contrast in multiple sclerosis (MS) patients. The goal of this work is to retrospectively generate realistic-looking MP2RAGE uniform images (UNI) from already acquired MPRAGE images in order to improve the automatic lesion and tissue segmentation.</p><p xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:p1=\"http://pubmed.gov/pub-one\" xmlns:xlink=\"http://www.w3.org/1999/xlink\">METHODS: For this task we propose a generative adversarial network (GAN). Multi-contrast MRI data of 12 healthy controls and 44 patients diagnosed with MS was retrospectively analyzed. Imaging was acquired at 3T using a SIEMENS scanner with MPRAGE, MP2RAGE, FLAIR, and DIR sequences. We train the GAN with both healthy controls and MS patients to generate synthetic MP2RAGE UNI images. These images were then compared to the real MP2RAGE UNI (considered as ground truth) analyzing the output of automatic brain tissue and lesion segmentation tools. Reference-based metrics as well as the lesion-wise true and false positives, Dice coefficient, and volume difference were considered for the evaluation. Statistical differences were assessed with the Wilcoxon signed-rank test.</p><p xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:p1=\"http://pubmed.gov/pub-one\" xmlns:xlink=\"http://www.w3.org/1999/xlink\">RESULTS: The synthetic MP2RAGE UNI significantly improves the lesion and tissue segmentation masks in terms of Dice coefficient and volume difference (p-values < 0.001) compared to the MPRAGE. For the segmentation metrics analyzed no statistically significant differences are found between the synthetic and acquired MP2RAGE UNI.</p><p xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:p1=\"http://pubmed.gov/pub-one\" xmlns:xlink=\"http://www.w3.org/1999/xlink\">CONCLUSION: Synthesized MP2RAGE UNI images are visually realistic and improve the output of automatic segmentation tools.</p><p>PMID:<a href=\"https://pubmed.ncbi.nlm.nih.gov/33711559/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210313085921&v=2.14.3\">33711559</a> | DOI:<a href=\"https://doi.org/10.1016/j.compbiomed.2021.104297\">10.1016/j.compbiomed.2021.104297</a></p></div>", "link": "https://pubmed.ncbi.nlm.nih.gov/33711559/#x3D;Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc&#x", "published_date": "2021-01-05T00:00:00Z", "sources": [ "PubMed" ], "teams": [ { "id": 1, "name": "Team Gregory" } ], "subjects": [ { "subject_name": "Multiple Sclerosis", "description": null } ], "publisher": "Elsevier BV", "container_title": "Computers in Biology and Medicine", "authors": [ { "author_id": 169944, "given_name": "Francesco", "family_name": "La Rosa", "ORCID": "http://orcid.org/0000-0002-9224-4664", "country": null }, { "author_id": 281404, "given_name": "Thomas", "family_name": "Yu", "ORCID": null, "country": null }, { "author_id": 281405, "given_name": "Germán", "family_name": "Barquero", "ORCID": null, "country": null }, { "author_id": 322824, "given_name": "Jean-Philippe", "family_name": "Thiran", "ORCID": "http://orcid.org/0000-0003-2938-9657", "country": "CH" }, { "author_id": 237094, "given_name": "Cristina", "family_name": "Granziera", "ORCID": null, "country": null }, { "author_id": 169952, "given_name": "Meritxell", "family_name": "Bach Cuadra", "ORCID": "http://orcid.org/0000-0003-2730-4285", "country": "CH" } ], "relevant": null, "ml_prediction_gnb": false, "ml_prediction_lr": false, "ml_prediction_lsvc": false, "discovery_date": "2021-03-13T13:59:23Z", "noun_phrases": [ "MPRAGE", "MP2RAGE UNI translation", "generative adversarial network", "the automatic tissue", "lesion segmentation", "multiple sclerosis patients" ], "doi": "10.1016/j.compbiomed.2021.104297", "access": "open", "takeaways": " The goal of this work is to retrospectively generate realistic-looking MP2RAGE uniform images (UNI) from already acquired MPRAGE images to improve the automatic lesion and tissue segmentation .", "categories": [] }, { "article_id": 525, "title": "The concurrence of multiple sclerosis and glioblastoma", "summary": "<div><p>Mult Scler Relat Disord. 2021 Mar 2;50:102877. doi: 10.1016/j.msard.2021.102877. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:p1=\"http://pubmed.gov/pub-one\" xmlns:xlink=\"http://www.w3.org/1999/xlink\">INTRODUCTION: Glioblastoma rarely coincides with multiple sclerosis. Although registries have reported a higher proportion of brain tumors-most of which are glial-these events appear to be underreported. The relative contribution of JC virus (an oncogenic virus) and disease modifying therapies that may facilitate JC virus neurotropism and tumor-specific immune evasion remain unknown.</p><p xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:p1=\"http://pubmed.gov/pub-one\" xmlns:xlink=\"http://www.w3.org/1999/xlink\">CASE REPORT: We present the case of a 64-year-old woman who developed a primary glioblastoma eight years after diagnosis of multiple sclerosis while on dimethyl fumarate.</p><p xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:p1=\"http://pubmed.gov/pub-one\" xmlns:xlink=\"http://www.w3.org/1999/xlink\">CONCLUSION: Systematic reporting may help answer whether JC virus seropositivity and certain disease modifying therapies confer higher risk for glioblastoma in patients with multiple sclerosis.</p><p>PMID:<a href=\"https://pubmed.ncbi.nlm.nih.gov/33711579/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210313085921&v=2.14.3\">33711579</a> | DOI:<a href=\"https://doi.org/10.1016/j.msard.2021.102877\">10.1016/j.msard.2021.102877</a></p></div>", "link": "https://pubmed.ncbi.nlm.nih.gov/33711579/#x3D;Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc&#x", "published_date": "2021-01-05T00:00:00Z", "sources": [ "PubMed" ], "teams": [ { "id": 1, "name": "Team Gregory" } ], "subjects": [ { "subject_name": "Multiple Sclerosis", "description": null } ], "publisher": "Elsevier BV", "container_title": "Multiple Sclerosis and Related Disorders", "authors": [ { "author_id": 147083, "given_name": "Samir", "family_name": "Alkabie", "ORCID": "http://orcid.org/0000-0001-5596-514X", "country": "CA" }, { "author_id": 255561, "given_name": "Rhaisa", "family_name": "Castrodad-Molina", "ORCID": null, "country": null }, { "author_id": 255563, "given_name": "Kent A.", "family_name": "Heck", "ORCID": null, "country": null }, { "author_id": 255565, "given_name": "Jacob", "family_name": "Mandel", "ORCID": null, "country": null }, { "author_id": 240387, "given_name": "George J.", "family_name": "Hutton", "ORCID": null, "country": null } ], "relevant": null, "ml_prediction_gnb": false, "ml_prediction_lr": false, "ml_prediction_lsvc": false, "discovery_date": "2021-03-13T13:59:23Z", "noun_phrases": [ "The concurrence", "multiple sclerosis", "glioblastoma" ], "doi": "10.1016/j.msard.2021.102877", "access": "restricted", "takeaways": " Glioblastoma rarely coincides with multiple sclerosis . Relative contribution of JC virus (an oncogenic virus) and disease modifying therapies that may facilitate JC virus neurotropism and tumor-specific immune evasion remain unknown .", "categories": [] }, { "article_id": 524, "title": "Impact of previous disease-modifying treatment on effectiveness and safety outcomes, among patients with multiple sclerosis treated with alemtuzumab", "summary": "<div><p>J Neurol Neurosurg Psychiatry. 2021 Mar 12:jnnp-2020-325304. doi: 10.1136/jnnp-2020-325304. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:p1=\"http://pubmed.gov/pub-one\" xmlns:xlink=\"http://www.w3.org/1999/xlink\">OBJECTIVES: Alemtuzumab is effective in patients with active multiple sclerosis but has a complex safety profile, including the development of secondary autoimmunity. Most of patients enrolled in randomised clinical trials with alemtuzumab were either treatment naïve or pretreated with injectable substances. Other previous disease-modifying treatments (DMTs) were not used in the study cohorts, and therefore, associated risks might yet remain unidentified.</p><p xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:p1=\"http://pubmed.gov/pub-one\" xmlns:xlink=\"http://www.w3.org/1999/xlink\">METHODS: We retrospectively evaluated a prospective dual-centre alemtuzumab cohort of 170 patients. We examined the baseline characteristics as well as safety and effectiveness outcomes, including the time to first relapse, the time to 3 months confirmed disability worsening and the time to secondary autoimmunity.</p><p xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:p1=\"http://pubmed.gov/pub-one\" xmlns:xlink=\"http://www.w3.org/1999/xlink\">RESULTS: The regression analysis showed that, among all previously used DMTs, the pretreatment with fingolimod (n=33 HRs for the time to first relapse (HR 5.420, 95% CI 2.520 to 11.660; p<0.001)) and for the time to worsening of disability (HR 7.676, 95% CI 2.870 to 20.534; p<0.001). Additionally, patients pretreated with fingolimod were more likely to experience spinal relapses (55% vs 10% among previously naïve patients; p<0.001) and had an increased risk of secondary autoimmunity (HR 5.875, 95% CI 2.126 to 16.27; p<0.001).</p><p xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:p1=\"http://pubmed.gov/pub-one\" xmlns:xlink=\"http://www.w3.org/1999/xlink\">CONCLUSION: In the real-world setting, we demonstrated suboptimal disease control and increased risk of secondary autoimmunity following alemtuzumab, among patients previously treated with fingolimod. These data can provide guidance for improving MS therapeutic management.</p><p>PMID:<a href=\"https://pubmed.ncbi.nlm.nih.gov/33712515/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210313085921&v=2.14.3\">33712515</a> | DOI:<a href=\"https://doi.org/10.1136/jnnp-2020-325304\">10.1136/jnnp-2020-325304</a></p></div>", "link": "https://pubmed.ncbi.nlm.nih.gov/33712515/?fc=20210216052009&ff=20210313085921&v=2.1", "published_date": "2021-01-09T00:00:00Z", "sources": [ "PubMed" ], "teams": [ { "id": 1, "name": "Team Gregory" } ], "subjects": [ { "subject_name": "Multiple Sclerosis", "description": null } ], "publisher": "BMJ", "container_title": "Journal of Neurology, Neurosurgery & Psychiatry", "authors": [ { "author_id": 183836, "given_name": "Steffen", "family_name": "Pfeuffer", "ORCID": "http://orcid.org/0000-0001-5171-4845", "country": null }, { "author_id": 172220, "given_name": "Tobias", "family_name": "Ruck", "ORCID": "http://orcid.org/0000-0001-6332-8650", "country": null }, { "author_id": 244245, "given_name": "Refik", "family_name": "Pul", "ORCID": null, "country": null }, { "author_id": 187920, "given_name": "Leoni", "family_name": "Rolfes", "ORCID": "http://orcid.org/0000-0003-4494-951X", "country": null }, { "author_id": 244246, "given_name": "Catharina", "family_name": "Korsukewitz", "ORCID": null, "country": null }, { "author_id": 172218, "given_name": "Marc", "family_name": "Pawlitzki", "ORCID": "http://orcid.org/0000-0003-3080-2277", "country": null }, { "author_id": 240370, "given_name": "Brigitte", "family_name": "Wildemann", "ORCID": null, "country": null }, { "author_id": 185561, "given_name": "Luisa", "family_name": "Klotz", "ORCID": "http://orcid.org/0000-0001-5439-9633", "country": null }, { "author_id": 185144, "given_name": "Christoph", "family_name": "Kleinschnitz", "ORCID": "http://orcid.org/0000-0002-1650-8875", "country": null }, { "author_id": 164225, "given_name": "Antonio", "family_name": "Scalfari", "ORCID": "http://orcid.org/0000-0002-7757-0293", "country": null }, { "author_id": 160394, "given_name": "Heinz", "family_name": "Wiendl", "ORCID": "http://orcid.org/0000-0003-4310-3432", "country": null }, { "author_id": 241498, "given_name": "Sven G", "family_name": "Meuth", "ORCID": null, "country": null } ], "relevant": true, "ml_prediction_gnb": true, "ml_prediction_lr": false, "ml_prediction_lsvc": true, "discovery_date": "2021-03-13T13:59:23Z", "noun_phrases": [ "Impact", "previous disease-modifying treatment", "effectiveness", "safety outcomes", "patients", "multiple sclerosis", "alemtuzumab" ], "doi": "10.1136/jnnp-2020-325304", "access": "open", "takeaways": " Alemtuzumab is effective in patients with active multiple sclerosis but has a complex safety profile, including the development of secondary autoimmunity . Other previous disease-modifying treatments (DMTs) were not used in the study cohorts .", "categories": [ { "category_id": 2, "category_description": "LEMTRADA, or Alemtuzumab, is a prescription medicine used to treat relapsing forms of multiple sclerosis (MS), to include relapsing-remitting disease and active secondary progressive disease, in adults. Since treatment with LEMTRADA can increase your risk of getting certain conditions and diseases, LEMTRADA is generally prescribed for people who have tried 2 or more MS medicines that have not worked well enough. LEMTRADA is not recommended for use in patients with clinically isolated syndrome (CIS). It is not known if LEMTRADA is safe and effective for use in children under 17 years of age.\n\nhttps://www.lemtrada.com/", "category_name": "Alemtuzumab", "category_slug": "alemtuzumab", "category_terms": [ "alemtuzumab", "lemtrada" ], "article_count": 118 } ] }, { "article_id": 523, "title": "Pathology-supported genetic testing as a method for disability prevention in multiple sclerosis (MS). Part II. Insights from two MS cases", "summary": "<div><p>Metab Brain Dis. 2021 Mar 12. doi: 10.1007/s11011-021-00712-9. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:p1=\"http://pubmed.gov/pub-one\" xmlns:xlink=\"http://www.w3.org/1999/xlink\">In Part I of this Review we evaluated the scientific evidence for a Metabolic Model of multiple sclerosis (MS). Part II outlines the implementation of an adaptive pathology-supported genetic testing (PSGT) algorithm aimed at preventing/reversing disability in two illustrative MS cases, starting with a questionnaire-based risk assessment, including family history and lifestyle factors. Measurement of iron, vitamin B12, vitamin D, cholesterol and homocysteine levels identified biochemical deficits in both cases. Case 1, after following the PSGT program for 15 years, had an expanded disability status scale (EDSS) of 2.0 (no neurological sequelae) together with preserved brain volume on magnetic resonance imaging (MRI). A novel form of iron deficiency was identified in Case 1, as biochemical testing at each hospital submission due to MS symptoms showed low serum iron, ferritin and transferrin saturation, while hematological status and erythrocyte sedimentation rate measurement of systemic inflammation remained normal. Case 2 was unable to walk unaided until her EDSS improved from 6.5 to 4.0 over 12 months after implementation of the PSGT program, with amelioration of her suboptimal biochemical markers and changes to her diet and lifestyle, allowing her to regain independence. Genotype-phenotype correlation using a pathway panel of functional single nucleotide variants (SNVs) to facilitate clinical interpretation of whole exome sequencing (WES), elucidated the underlying metabolic pathways related to the biochemical deficits. A cure for MS will remain an elusive goal if separated from nutritional support required for production and maintenance of myelin, which can only be achieved by a lifelong investment in wellness.</p><p>PMID:<a href=\"https://pubmed.ncbi.nlm.nih.gov/33710528/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210312195920&v=2.14.3\">33710528</a> | DOI:<a href=\"https://doi.org/10.1007/s11011-021-00712-9\">10.1007/s11011-021-00712-9</a></p></div>", "link": "https://pubmed.ncbi.nlm.nih.gov/33710528/#x3D;Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc&#x", "published_date": "2021-01-08T00:00:00Z", "sources": [ "PubMed" ], "teams": [ { "id": 1, "name": "Team Gregory" } ], "subjects": [ { "subject_name": "Multiple Sclerosis", "description": null } ], "publisher": "Springer Science and Business Media LLC", "container_title": "Metabolic Brain Disease", "authors": [ { "author_id": 174461, "given_name": "Susan J.", "family_name": "van Rensburg", "ORCID": "http://orcid.org/0000-0002-2437-8978", "country": null }, { "author_id": 252267, "given_name": "Coenraad", "family_name": "Hattingh", "ORCID": null, "country": null }, { "author_id": 174464, "given_name": "Kelebogile E.", "family_name": "Moremi", "ORCID": "http://orcid.org/0000-0003-1105-1578", "country": null }, { "author_id": 223783, "given_name": "Armand V.", "family_name": "Peeters", "ORCID": "http://orcid.org/0000-0002-7155-8226", "country": null }, { "author_id": 223784, "given_name": "Carel J.", "family_name": "van Heerden", "ORCID": "http://orcid.org/0000-0003-1786-7527", "country": "ZA" }, { "author_id": 174463, "given_name": "Rajiv T.", "family_name": "Erasmus", "ORCID": "http://orcid.org/0000-0001-6831-4215", "country": null }, { "author_id": 223785, "given_name": "Annalise E.", "family_name": "Zemlin", "ORCID": "http://orcid.org/0000-0001-7621-4679", "country": null }, { "author_id": 174465, "given_name": "Merlisa C.", "family_name": "Kemp", "ORCID": "http://orcid.org/0000-0001-5126-6982", "country": null }, { "author_id": 252270, "given_name": "Aye Aye", "family_name": "Khine", "ORCID": null, "country": null }, { "author_id": 252271, "given_name": "Felix C.V.", "family_name": "Potocnik", "ORCID": null, "country": null }, { "author_id": 252272, "given_name": "Lindiwe", "family_name": "Whati", "ORCID": null, "country": null }, { "author_id": 174466, "given_name": "Penelope", "family_name": "Engel-Hills", "ORCID": "http://orcid.org/0000-0002-1084-769X", "country": null }, { "author_id": 174462, "given_name": "Ronald", "family_name": "van Toorn", "ORCID": "http://orcid.org/0000-0002-2689-065X", "country": null }, { "author_id": 174467, "given_name": "Maritha J.", "family_name": "Kotze", "ORCID": "http://orcid.org/0000-0002-6050-2876", "country": null }, { "author_id": 329353, "given_name": "Clint", "family_name": "Johannes", "ORCID": "http://orcid.org/0009-0002-4358-9495", "country": "ZA" }, { "author_id": 329354, "given_name": "Mariaan", "family_name": "Jaftha", "ORCID": "http://orcid.org/0000-0003-2929-0972", "country": null } ], "relevant": null, "ml_prediction_gnb": false, "ml_prediction_lr": false, "ml_prediction_lsvc": false, "discovery_date": "2021-03-13T00:59:21Z", "noun_phrases": [ "Pathology-supported genetic testing", "a method", "disability prevention", "multiple sclerosis", "MS", "Part II", "Insights", "two MS cases" ], "doi": "10.1007/s11011-021-00712-9", "access": "restricted", "takeaways": " Measurement of iron, vitamin B12, vitamin D, cholesterol and homocysteine levels identified biochemical deficits in both cases . Case 1 had an expanded disability status scale (EDSS) of 2.0 (no neurological sequelae) Case 2 was unable to walk unaided until her EDSS improved from 6.5 to 4.0 over 12 months after implementation of the PSGT program .", "categories": [] }, { "article_id": 521, "title": "Staging of astrocytopathy and complement activation in neuromyelitis optica spectrum disorders", "summary": "<div><p>Brain. 2021 Mar 12:awab102. doi: 10.1093/brain/awab102. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:p1=\"http://pubmed.gov/pub-one\" xmlns:xlink=\"http://www.w3.org/1999/xlink\">Aquaporin 4 (AQP4)-IgG-positive neuromyelitis optica spectrum disorder (AQP4-IgG+NMOSD) is an autoimmune astrocytopathic disease pathologically characterized by the massive destruction and regeneration of astrocytes with diverse types of tissue injury with or without complement deposition. However, it is unknown whether this diversity is derived from differences in pathological processes or temporal changes. Furthermore, unlike for the demyelinating lesions in multiple sclerosis, there has been no staging of astrocytopathy in AQP4-IgG+NMOSD based on astrocyte morphology. Therefore, we classified astrocytopathy of the disease by comparing the characteristic features, such as AQP4 loss, inflammatory cell infiltration, complement deposition and demyelination activity, with the clinical phase. We performed histopathological analyses in eight autopsied cases of AQP4-IgG+NMOSD. There were six women and two men, with a median age of 56.5 years (range, 46-71 years) and a median disease duration of 62.5 months (range, 0.6-252 months). Astrocytopathy in AQP4-IgG+NMOSD was classified into the following four stages defined by the astrocyte morphology and immunoreactivity for glial fibrillary acidic protein (GFAP): (a) astrocyte lysis: Extensive loss of astrocytes with fragmented and/or dust-like particles; (b) progenitor recruitment: Loss of astrocytes except small nucleated cells with GFAP-positive fibre-forming foot processes; (c) protoplasmic gliosis: Presence of star-shaped astrocytes with abundant GFAP-reactive cytoplasm; and (d) fibrous gliosis: Lesions composed of densely packed mature astrocytes. The astrocyte lysis and progenitor recruitment stages dominated in clinically acute cases (within 2 months after the last recurrence). Findings common to both stages were the loss of AQP4, a decreased number of oligodendrocytes, the selective loss of myelin-associated glycoprotein and active demyelination with phagocytic macrophages. The infiltration of polymorphonuclear cells and T cells (CD4-dominant) and the deposition of activated complement (C9neo), which reflects the membrane attack complex, a hallmark of acute NMOSD lesions, were selectively observed in the astrocyte lysis stage (98.4% in astrocyte lysis, 1.6% in progenitor recruitment, and 0% in protoplasmic gliosis and fibrous gliosis). Although most of the protoplasmic gliosis and fibrous gliosis lesions were accompanied by inactive demyelinated lesions with a low amount of inflammatory cell infiltration, the deposition of complement degradation product (C3d) was observed in all four stages, even in fibrous gliosis lesions, suggesting the past or chronic occurrence of complement activation, which is a useful finding to distinguish chronic lesions in NMOSD from those in multiple sclerosis. Our staging of astrocytopathy is expected to be useful for understanding the unique temporal pathology of AQP4-IgG+NMOSD.</p><p>PMID:<a href=\"https://pubmed.ncbi.nlm.nih.gov/33711152/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210312195920&v=2.14.3\">33711152</a> | DOI:<a href=\"https://doi.org/10.1093/brain/awab102\">10.1093/brain/awab102</a></p></div>", "link": "https://pubmed.ncbi.nlm.nih.gov/33711152/#x3D;Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc&#x", "published_date": "2021-09-03T23:00:00Z", "sources": [ "PubMed" ], "teams": [ { "id": 1, "name": "Team Gregory" } ], "subjects": [ { "subject_name": "Multiple Sclerosis", "description": null } ], "publisher": "Oxford University Press (OUP)", "container_title": "Brain", "authors": [ { "author_id": 241749, "given_name": "Yoshiki", "family_name": "Takai", "ORCID": null, "country": null }, { "author_id": 230358, "given_name": "Tatsuro", "family_name": "Misu", "ORCID": "http://orcid.org/0000-0002-7311-2578", "country": null }, { "author_id": 244097, "given_name": "Hiroyoshi", "family_name": "Suzuki", "ORCID": null, "country": null }, { "author_id": 241744, "given_name": "Toshiyuki", "family_name": "Takahashi", "ORCID": null, "country": null }, { "author_id": 244098, "given_name": "Hiromi", "family_name": "Okada", "ORCID": null, "country": null }, { "author_id": 244099, "given_name": "Shinya", "family_name": "Tanaka", "ORCID": null, "country": null }, { "author_id": 244100, "given_name": "Kenji", "family_name": "Okita", "ORCID": null, "country": null }, { "author_id": 244101, "given_name": "Shunichi", "family_name": "Sasou", "ORCID": null, "country": null }, { "author_id": 244102, "given_name": "Mika", "family_name": "Watanabe", "ORCID": null, "country": null }, { "author_id": 244103, "given_name": "Chihiro", "family_name": "Namatame", "ORCID": null, "country": null }, { "author_id": 244106, "given_name": "Hirohiko", "family_name": "Ono", "ORCID": null, "country": null }, { "author_id": 243805, "given_name": "Kimihiko", "family_name": "Kaneko", "ORCID": null, "country": null }, { "author_id": 241751, "given_name": "Shuhei", "family_name": "Nishiyama", "ORCID": null, "country": null }, { "author_id": 244110, "given_name": "Hiroshi", "family_name": "Kuroda", "ORCID": null, "country": null }, { "author_id": 150220, "given_name": "Ichiro", "family_name": "Nakashima", "ORCID": "http://orcid.org/0000-0002-2612-8948", "country": "JP" }, { "author_id": 160015, "given_name": "Hans", "family_name": "Lassmann", "ORCID": "http://orcid.org/0000-0001-8617-5052", "country": null }, { "author_id": 241745, "given_name": "Kazuo", "family_name": "Fujihara", "ORCID": null, "country": null }, { "author_id": 244115, "given_name": "Yasuto", "family_name": "Itoyama", "ORCID": null, "country": null }, { "author_id": 241757, "given_name": "Masashi", "family_name": "Aoki", "ORCID": null, "country": null }, { "author_id": 332586, "given_name": "Yuki", "family_name": "Matsumoto", "ORCID": "http://orcid.org/0000-0003-0163-8105", "country": null } ], "relevant": null, "ml_prediction_gnb": false, "ml_prediction_lr": false, "ml_prediction_lsvc": false, "discovery_date": "2021-03-13T00:59:21Z", "noun_phrases": [ "Staging", "astrocytopathy and complement activation", "neuromyelitis optica spectrum disorders" ], "doi": "10.1093/brain/awab102", "access": "open", "takeaways": " Histopathological analyses in eight autopsied cases of AQP4-IgG+NMOSD . The astrocytopathy of the disease was classified into four stages .", "categories": [] }, { "article_id": 522, "title": "How to measure fluctuating impairments in people with MS: development of an ambulatory assessment version of the EQ-5D-5L in an exploratory study", "summary": "<div><p>Qual Life Res. 2021 Mar 12. doi: 10.1007/s11136-021-02802-8. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:p1=\"http://pubmed.gov/pub-one\" xmlns:xlink=\"http://www.w3.org/1999/xlink\">BACKGROUND: Health fluctuations even within a single day are typical in multiple sclerosis (MS), but are not captured by widely used questionnaires like the EQ-5D-5L. This exploratory study aimed to develop an ambulatory assessment (AA) version of the EQ-5D-5L (EQ-5D-AA) where patients rate their health on mobile phones multiple times per day over several days, and to assess its feasibility and face validity.</p><p xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:p1=\"http://pubmed.gov/pub-one\" xmlns:xlink=\"http://www.w3.org/1999/xlink\">METHODS: An initial EQ-5D-AA version was based on two patient focus groups. It was then tested and continuously developed in an iterative process: patients completed it over several days, followed by debriefing interviews. Findings were used to refine the EQ-5D-AA, with the resulting version being tested by the subsequent wave of patients until participants declared no need for changes anymore. Before and after the AA period, participants completed the standard paper-based EQ-5D-5L asking about 'today'.</p><p xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:p1=\"http://pubmed.gov/pub-one\" xmlns:xlink=\"http://www.w3.org/1999/xlink\">RESULTS: Focus group participants reported that their impairments often fluctuated between and within days. They regarded an AA with three assessments per day over seven days most appropriate; assessment should be retrospective to the previous assessment, but not all items should be assessed at each time point. Four waves of AA testing were conducted. Thirteen out of the 17 participants preferred the AA over standard assessment as they regarded it more informative, but not too burdensome.</p><p xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:p1=\"http://pubmed.gov/pub-one\" xmlns:xlink=\"http://www.w3.org/1999/xlink\">CONCLUSION: The newly developed one-week AA of the EQ-5D-5L captures within-day and day-to-day health fluctuations in people with MS. From the patients' perspective, it is a feasible and face valid way to provide important information beyond what is captured by the standard EQ-5D-5L.</p><p>PMID:<a href=\"https://pubmed.ncbi.nlm.nih.gov/33710593/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210312195920&v=2.14.3\">33710593</a> | DOI:<a href=\"https://doi.org/10.1007/s11136-021-02802-8\">10.1007/s11136-021-02802-8</a></p></div>", "link": "https://pubmed.ncbi.nlm.nih.gov/33710593/#x3D;Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc&#x", "published_date": "2021-01-07T00:00:00Z", "sources": [ "PubMed" ], "teams": [ { "id": 1, "name": "Team Gregory" } ], "subjects": [ { "subject_name": "Multiple Sclerosis", "description": null } ], "publisher": "Springer Science and Business Media LLC", "container_title": "Quality of Life Research", "authors": [ { "author_id": 197029, "given_name": "Christine", "family_name": "Blome", "ORCID": "http://orcid.org/0000-0002-1163-1639", "country": "DE" }, { "author_id": 198050, "given_name": "Jill", "family_name": "Carlton", "ORCID": "http://orcid.org/0000-0002-9373-7663", "country": "GB" }, { "author_id": 162588, "given_name": "Christoph", "family_name": "Heesen", "ORCID": "http://orcid.org/0000-0001-8131-9467", "country": null }, { "author_id": 198051, "given_name": "Mathieu F.", "family_name": "Janssen", "ORCID": "http://orcid.org/0000-0001-6602-6949", "country": null }, { "author_id": 193100, "given_name": "Andrew", "family_name": "Lloyd", "ORCID": "http://orcid.org/0000-0002-7597-6556", "country": null }, { "author_id": 198052, "given_name": "Marina", "family_name": "Otten", "ORCID": "http://orcid.org/0000-0003-3767-1548", "country": null }, { "author_id": 198053, "given_name": "John", "family_name": "Brazier", "ORCID": "http://orcid.org/0000-0001-8645-4780", "country": null } ], "relevant": null, "ml_prediction_gnb": false, "ml_prediction_lr": false, "ml_prediction_lsvc": false, "discovery_date": "2021-03-13T00:59:21Z", "noun_phrases": [ "impairments", "people", "MS", "development", "an ambulatory assessment version", "the EQ-5D-5L", "an exploratory study" ], "doi": "10.1007/s11136-021-02802-8", "access": "open", "takeaways": " New ambulatory assessment (AA) version of the EQ-5D-5L . Patients rate their health on mobile phones multiple times per day over several days .", "categories": [] }, { "article_id": 519, "title": "Isolated thoracic intramedullary Erdheim-Chester disease presenting with paraplegia: a case report and literature review", "summary": "Background: Erdheim-Chester disease (ECD) is a rare, idiopathic, systemic non-Langerhans cell histiocytosis involving long bone and visceral organs. Central nervous system (CNS) involvement is uncommon and most cases develop as a part of systemic disease. We present a rare case of variant ECD as an isolated intramedullary tumor.Case presentationA 75-year-old female patient with a medical history of diabetes and hypertension presented with sudden-onset flaccid paraparesis for 1 day. Neurological examination revealed grade 2–3 weakness in both legs, decreased deep tendon reflex, loss of anal tone, and numbness below T4. Leg weakness deteriorated to G1 before surgery. Preoperative magnetic resonance imaging (MRI) and 18F-fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) showed an intramedullary mass lesion at T2-T4 with no systemic lesion, which was heterogeneous enhancement pattern with cord swelling and edema from C7 to T6. Gross total removal was achieved for the white-gray-colored and soft-natured intramedullary mass lesion with an ill-defined boundary. Histological finding revealed benign histiocytic proliferation with foamy histiocytes and uniform nuclei. We concluded it as an isolated intramedullary ECD. The patient showed self-standing and walkable at 18-month with no evidence of recurrence and new lesion on spine MRI and whole-body FDG-PET/CT until sudden occurrence of unknown originated thoracic cord infarction.ConclusionsWe experienced an extremely rare case of isolated intramedullary ECD, which was controlled by surgical resection with no adjuvant therapy. Histological examination is the most important for final diagnosis, and careful serial follow-up after surgical resection is required to identify the recurrence and progression to systemic disease.", "link": "https://bmcmusculoskeletdisord.biomedcentral.com/articles/10.1186/s12891-021-04061-7", "published_date": "2021-03-12T00:00:00Z", "sources": [ "BioMedCentral" ], "teams": [ { "id": 1, "name": "Team Gregory" } ], "subjects": [ { "subject_name": "Multiple Sclerosis", "description": null } ], "publisher": "Springer Science and Business Media LLC", "container_title": "BMC Musculoskeletal Disorders", "authors": [ { "author_id": 244086, "given_name": "Ikchan", "family_name": "Jeon", "ORCID": null, "country": null }, { "author_id": 244087, "given_name": "Joon Hyuk", "family_name": "Choi", "ORCID": null, "country": null } ], "relevant": null, "ml_prediction_gnb": false, "ml_prediction_lr": false, "ml_prediction_lsvc": false, "discovery_date": "2021-03-12T19:59:51Z", "noun_phrases": [ "Isolated thoracic intramedullary Erdheim-Chester disease", "paraplegia", "a case report", "literature review" ], "doi": "10.1186/s12891-021-04061-7", "access": "open", "takeaways": " Erdheim-Chester disease (ECD) is a rare, idiopathic, systemic non-Langerhans cell histiocytosis involving long bone and visceral organs . 75-year-old female patient with a medical history of diabetes and hypertension presented with sudden-onset flaccid paraparesis for 1 day . Neurological examination revealed grade 2–3 weakness in both legs, decreased deep tendon reflex, loss of anal tone, and numbness below T4 . MRI and FDG-PET/CT showed intramedullary mass lesion at T2-", "categories": [] }, { "article_id": 518, "title": "Identification of lncRNAs associated with the pathogenesis of ankylosing spondylitis", "summary": "Background: Ankylosing spondylitis (AS) is a chronic autoimmune disease affecting the sacroiliac joint. To date, few studies have examined the association between long non-coding RNAs (lncRNAs) and AS pathogenesis. As such, we herein sought to characterize patterns of AS-related lncRNA expression and to evaluate the potential role played by these lncRNAs in this complex autoimmune context.MethodsWe conducted a RNA-seq analysis of peripheral blood mononuclear cell (PBMC) samples isolated from five AS patients and corresponding controls. These data were then leveraged to characterize AS-related lncRNA expression patterns. We further conducted GO and KEGG enrichment analyses of the parental genes encoding these lncRNAs, and we confirmed the validity of our RNA-seq data by assessing the expression of six lncRNAs via qRT-PCR in 15 AS and control patient samples. Pearson correlation analyses were additionally employed to examine the associations between the expression levels of these six lncRNAs and patient clinical index values.ResultsWe detected 56,575 total lncRNAs in AS and control patient samples during our initial RNA-seq analysis, of which 200 and 70 were found to be up- and down-regulated (FC > 2 or < 0.05; P < 0.05), respectively, in AS samples relative to controls. In qRT-PCR validation assays, we confirmed the significant upregulation of NONHSAT118801.2, ENST00000444046, and NONHSAT183847.1 and the significant downregulation of NONHSAT205110.1, NONHSAT105444.2, and NONHSAT051856.2 in AS patient samples. We further found the expression of NONHSAT118801.2 and NONHSAT183847.1 to be positively correlated with disease severity.ConclusionOverall, our findings highlight several lncRNAs that are specifically expressed in PBMCs of AS patients, indicating that they may play key functions in the pathogenesis of this autoimmune disease. Specifically, we determined that NONHSAT118801.2 and NONHSAT183847.1 may influence the occurrence and development of AS.", "link": "https://bmcmusculoskeletdisord.biomedcentral.com/articles/10.1186/s12891-021-04119-6", "published_date": "2021-03-12T00:00:00Z", "sources": [ "BioMedCentral" ], "teams": [ { "id": 1, "name": "Team Gregory" } ], "subjects": [ { "subject_name": "Multiple Sclerosis", "description": null } ], "publisher": "Springer Science and Business Media LLC", "container_title": "BMC Musculoskeletal Disorders", "authors": [ { "author_id": 296099, "given_name": "Dan", "family_name": "Huang", "ORCID": null, "country": null }, { "author_id": 201020, "given_name": "Jian", "family_name": "Liu", "ORCID": "http://orcid.org/0000-0003-3101-7553", "country": null }, { "author_id": 296100, "given_name": "Lei", "family_name": "Wan", "ORCID": null, "country": null }, { "author_id": 296101, "given_name": "Yanyan", "family_name": "Fang", "ORCID": null, "country": null }, { "author_id": 296102, "given_name": "Yan", "family_name": "Long", "ORCID": null, "country": null }, { "author_id": 248014, "given_name": "Ying", "family_name": "Zhang", "ORCID": null, "country": null }, { "author_id": 296103, "given_name": "Bingxi", "family_name": "Bao", "ORCID": null, "country": null } ], "relevant": null, "ml_prediction_gnb": false, "ml_prediction_lr": false, "ml_prediction_lsvc": false, "discovery_date": "2021-03-12T19:59:51Z", "noun_phrases": [ "Identification", "lncRNAs", "the pathogenesis", "ankylosing spondylitis" ], "doi": "10.1186/s12891-021-04119-6", "access": "open", "takeaways": " Ankylosing spondylitis (AS) is a chronic autoimmune disease affecting the sacroiliac joint . Few studies have examined the association between long non-coding RNAs (lncRNAs) and AS pathogenesis .", "categories": [] }, { "article_id": 515, "title": "Clinical characteristics, inflammation and coagulation status in patients with immunological disease-related chronic cerebrospinal venous insufficiency", "summary": "<div><p>Ann Transl Med. 2021 Feb;9(3):236. doi: 10.21037/atm-20-4201.</p><p><b>ABSTRACT</b></p><p xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:p1=\"http://pubmed.gov/pub-one\" xmlns:xlink=\"http://www.w3.org/1999/xlink\">BACKGROUND: Immunological disease-related chronic cerebrospinal venous insufficiency (CCSVI) is rarely reported. This study aimed to analyze clinical characteristics, inflammation, and coagulation status in patients with immunological disease-related CCSVI.</p><p xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:p1=\"http://pubmed.gov/pub-one\" xmlns:xlink=\"http://www.w3.org/1999/xlink\">METHODS: Patients with CCSVI were enrolled from 2017 to 2019 and divided into three cohorts based on their immunological disease backgrounds, including groups with confirmed autoimmune disease, with suspected/subclinical autoimmune disease, and with non-immunological etiology. Immunological, inflammatory, and thrombophilia biomarker assay in blood samples were obtained. Mann-Whitney U test or Fisher's exact test was used to compare continuous variables or categorical variables between the CCSVI patients with or without the immunological etiology. Spearman's correlation analysis was conducted among age, baseline neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), interleukin-6 (IL-6), C-reactive protein (CRP), and neuron-specific enolase (NSE) in the three groups.</p><p xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:p1=\"http://pubmed.gov/pub-one\" xmlns:xlink=\"http://www.w3.org/1999/xlink\">RESULTS: A total of 255 consecutive patients with CCSVI were enrolled, including three subgroups: CCSVI with confirmed autoimmune disease (n=41), CCSVI with suspected/subclinical autoimmune disease (n=116) and CCSVI with non-immunological etiology (n=98). In the first subgroup, a series of 41 cases was confirmed with eight different autoimmune diseases including antiphospholipid syndrome (n=18), Sjögren's syndrome (n=8), immunoglobulin G4-related disease (n=7), Behçet's disease (n=2), autoimmune hepatitis (n=2), Wegener's granulomatosis (n=2), systemic sclerosis (n=1) and AQP4 antibody-positive neuromyelitis optica spectrum disorder (n=1). Groups with immunological etiology did not show a higher incidence of thrombophilia or increased pro-inflammatory biomarkers (e.g., neutrophil, IL-6). However, patients with non-immunological etiology had a higher baseline level of CRP. Additionally, baseline PLR was moderately correlated to NLR and CRP in CCSVI patients with non-immunological etiology and suspected/subclinical autoimmune disease.</p><p xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:p1=\"http://pubmed.gov/pub-one\" xmlns:xlink=\"http://www.w3.org/1999/xlink\">CONCLUSIONS: The formation of CCSVI may be based on the inflammatory process, facilitated by multiple risk factors, among which medical history of immunological diseases may play a significant role due to the intricate relationship between inflammation and coagulation. Moreover, CCSVI may also cause an independent inflammatory injury in venous walls, leading to focal stenosis or thrombus, without attacks from autoimmune antibodies.</p><p>PMID:<a href=\"https://pubmed.ncbi.nlm.nih.gov/33708863/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210312131920&v=2.14.3\">33708863</a> | PMC:<a href=\"https://www.ncbi.nlm.nih.gov/pmc/PMC7940939/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210312131920&v=2.14.3\">PMC7940939</a> | DOI:<a href=\"https://doi.org/10.21037/atm-20-4201\">10.21037/atm-20-4201</a></p></div>", "link": "https://pubmed.ncbi.nlm.nih.gov/33708863/#x3D;Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc&#x", "published_date": "2021-01-02T00:00:00Z", "sources": [ "PubMed" ], "teams": [ { "id": 1, "name": "Team Gregory" } ], "subjects": [ { "subject_name": "Multiple Sclerosis", "description": null } ], "publisher": "AME Publishing Company", "container_title": "Annals of Translational Medicine", "authors": [ { "author_id": 295064, "given_name": "Si-Ying", "family_name": "Song", "ORCID": null, "country": null }, { "author_id": 295065, "given_name": "Duo", "family_name": "Lan", "ORCID": null, "country": null }, { "author_id": 295066, "given_name": "Xiao-Qin", "family_name": "Wu", "ORCID": null, "country": null }, { "author_id": 295067, "given_name": "Yu-Chuan", "family_name": "Ding", "ORCID": null, "country": null }, { "author_id": 295068, "given_name": "Xun-Ming", "family_name": "Ji", "ORCID": null, "country": null }, { "author_id": 295069, "given_name": "Ran", "family_name": "Meng", "ORCID": null, "country": null } ], "relevant": null, "ml_prediction_gnb": false, "ml_prediction_lr": false, "ml_prediction_lsvc": false, "discovery_date": "2021-03-12T18:19:22Z", "noun_phrases": [ "Clinical characteristics", "inflammation", "coagulation", "status", "patients", "immunological disease-related chronic cerebrospinal venous insufficiency" ], "doi": "10.21037/atm-20-4201", "access": "open", "takeaways": " Chronic cerebrospinal venous insufficiency (CCSVI) is rarely reported . Study aimed to analyze clinical characteristics, inflammation, and coagulation status in patients with immunological disease-related CCSVI .", "categories": [] } ] }